1. Introduction

Meningiomas are hormone related, slowly growing CNS neoplasms, usually considered to be benign and resulting from meningothelial cells. Meningiomas could be subcategorized as grade I, II and III based on the subtyping of the WHO. Even though, most of the tumors are benign and of WHO grade I; II (atypical) and III (anaplastic) lesions are not uncommon and demonstrate a greater affinity to metastasize or recur after treatment in comparison with those of grade I.1,2

The clinical outcome of meningiomas cannot always be predicted by histopathology alone; 2-3% of histologically benign meningiomas recur following macroscopically complete surgical removal, while some others present an exceptionally rapid growth in the absence of histological evidence of atypia.3 However, meningiomas are considered as primarily benign tumours however, some meningiomas have aggressive characteristics with cerebral invasion, metastasis, and fatal outcome. Ki-67 and its formalin resistant MIB-1, both react with a nuclear antigen expressed by proliferating cells, thus providing a measurement for the growth fraction in individual tumors.4

Speculations that meningiomas are subject to gender specific hormone influence is supported by their higher incidence in females, their documented association with breast carcinomas in the same patients and reports of exacerbation of symptoms during pregnancy and the luteal phase of the menstrual cycle.5 Hormone receptor status in meningiomas has been recognized as follows, despite frequent discrepancies in the literature. The level of ER has always been equivocal, ranging from low to almost untraceable by immunohistochemistry whereas a high levels of PR has high percentage of tumours display.6
The prognostic role of ER and PR has been extensively discussed in different circumstances, predominantly in breast cancer, in cases with hepatotoxicity, some bacterial infections, cancers in animals, malignant and benign skin lesions and tongue carcinoma; the role of PR and ER is even more widespread for the status of Ki-67; such as the role of these factors in meningioma, however, is not fully understood and ongoing debate is still present in the literature. Therefore the present study was undertaken to investigate the presence of ER and PR, and their relation to proliferative marker Ki-67.

2. Materials and Methods

This prospective non-randomized trial was conducted in 75 diagnosed cases of meningioma at Bangur Institute of Neurosciences (BIN) & S.S.K.M. Hospital Kolkata over a period of 2yrs from January 2014 to December 2015. All cases of meningioma diagnosed on radiological basis conformed on histopathology were included while patients not giving consent for operation and performance of receptor analysis were excluded. After the subject’s guardian had been given a complete description of the study, written informal consents were obtained. The protocol was approved by ethical committee of IPGMER, SSKM Hospital Kolkata.

All the patients were resected at the initial operation. Resection was based on the surgeon’s assessment at the time of surgery. Complete clinical record and data for cases, including the age at resection, sex, radiographic and discharge summaries, site of the tumour, was submitted by the respective neurosurgeon. The cases were operated in Bangur Institute of Neurosciences, Faculty of Neurosurgery, West Bengal University of Health Sciences, whereas the histopathological assessment to be done in Pathology Department, I.P.G.M.E.R, SSKM, West Bengal University of Health Sciences. Each paraffin block was re-cut by microtome at 5μ, section was stained with Haematoxylin and Eosin for regular histopathological investigation and immunohistochemical staining against ER, PR and Ki-67 using mouse monoclonal antibodies anti-estrogen, anti-progesterone and anti-Ki-67/MIB-1 antibodies was done. Parameters studied were ER, PR receptor status and Ki-67 labelling index and relationship of receptor status with grade of tumour.

3. Results

Total 75 cases of meningioma were studied with age range of 21 years to 70 years; It was found that there is increase in incidence in middle age with maximum incidence in 41-50 years. There were 25 male and 50 female patients. As per the location, 70(93.33%) were cranial and 5 cases (6.67%) were spinal meningioma. According to histological type, meningotheelial meningioma among 75 meningioma patients were 30 (40%), those having histopathology report of transitional were 25 (33.33%), patients having Fibrous histopathology were 4 (5.33%), secretory histopathology was in 5 cases (6.66%), angioblastic in 3 (4%), psammomatous in 2 (2.66%) cases, and there were no cases of microcystic, lymphoplasmacyte rich and metaplastic meningioma in our series.

The patient were graded as per the WHO 2007 grading system, in grade I there were 69 patients (92%), grade II meningioma were 5 (6.67%). and, in grade III meningioma was 1(1.33%) patients.

Among 75 cases of meningioma 50 (66.67%) cases were positive for PR and negative for ER. 15 (20%) cases were negative for both PR and ER, 5 (6.67%) cases were positive for both PR and ER, and 5 (6.66%) cases were negative for PR but positive for ER.

The total number of cases positive for PR were 55(73.33%) and all were WHO grade 1 meningioma, and total cases positive for estrogen receptors were 10 (13.33%).

Out of 50 female patients, 45 (90%) patients were positive for PR, and out of 25 male patients, 10 (40%) patients were positive for PR showing association of progesterone receptor positivity with female gender.(p<0.001).

![Fig. 1: Estrogen and Progesteron Receptor Status](image)

Progesterone receptor was found positive in 55 cases (77.46%) primary meningioma out of 71 cases and all 4 cases of recurrent meningioma were negative for progesterone receptor. It indicates that primary meningiomas are more associated with PR positive (p<0.001).

Among 75 cases of meningioma, 64 patients (85.33%) were having Ki 67 labeling index below range of 1-4% which were largely grade1, 10 patients (13.33%) were having Ki-67 Li in the range of 5-10% which were mainly...
grade 2, only 1 patient had Ki 67 LI of 14% which was grad 3 tumour.

Mean Ki-67 Labelling index in 55 cases of progesterone positive meningioma was 1.13%, compared to 3.75% mean Ki 67 labeling index in progesterone negative meningioma, (Table 1), indicating higher mitosis and proliferation in progesterone receptor negative meningioma (Pearson coefficient-5.77, p value<0.001).

Table 1: Correlation between progesterone receptors status and Ki-67 labeling index

| Progesterone receptor status | Positive (55 Patients) | Negative (25 Patients) |
|-----------------------------|------------------------|------------------------|
| Mean Ki 67 labeling index   | 1.13%                  | 3.75%                  |

We determined Ki-67 LIs of all the 75 cases Mean Ki 67 labeling index in male was 2.4% which was much more than mean Ki 67 labeling in Female patients 1.54%, (Pearson coefficient-5.33, p value<0.001).

4. Discussion

Several scientific studies have been carried out till date to investigate the role of Ki-67 and PR, ER in meningioma and also to evaluate their significance in predicting the behaviour of meningioma as prognostic factors. On the other hand the different studies had given varied propositions regarding the correlation of PR and Ki-67, ER expression with the biological behaviour of meningioma. Histopathologically in present series out of 75 cases, 30 (40%) were meningothelial, 25 (33.33%) transitional, 5 (6.66%) secretory, 4 (5.33%) fibrous, 2 (2.66%) psammomatous, three (4%) were angiomatous, and there were 2 cases of atypical and clear cell meningioma each (2.66% each), and one (1.33%) case of chordoid and one (1.33%) case of papillary meningioma. These results are similar with that of Gursan et al study. Out our results differ from Mukherjee et al in which there is similar percentage of meningiothelial meningioma (36.7%) but lower percentage of transitional meningioma (13.4%) and higher percentage of fibrous meningioma (21.6%).

As per histological grade, the present study found that 69 (92%) cases of Grade I meningioma, 5 (6.66%) cases of atypical meningiomas i.e. Grade II and only 1 (1.33%) case of anaplastic meningioma i.e. Grade III. Similar to Mukherjee et al and Nagashima et al, the present study constituted 8% of total cases of atypical and anaplastic meningiomas. The mean Ki-67 LIs was found significantly higher in male patients (2.4%) than female patients (1.5%) like the study done by Mukherjee et al Matsuno et al. This gender difference revealed the greater incidence of non-benign meningioma in males.

Ki-67 LIs of 75 meningiomas ranging between 1 to 14% which is coincide with the findings of Nagashima et al that is 0.4 to 16.4%. Likewise Ki-67 LIs found significantly higher in Grade II meningioma than Grade I as reported in previous studies. The statistically significant difference was observed in Ki-67 LIs in recurrent and non-recurrent meningiomas which resemble with the results of Matsuno et al, Abramovich et al and Miyagami et al. In non-recurrent tumors, the mean Ki-67 LI was 1.56% whereas recurrent tumors showed LI of 7.25% which correlated with the previous studies.

The PR positivity in present study was found to be 73.33% of total cases and similar percentage was found with the study done by Mukherjee et al and other authors. The PR immunostaining was more abundant in female that is 90% in females and 40% in males which revealed statistically significant gender-related difference. In support of this, the previous studies also demonstrated a significant gender difference in the expression of the PR which is attributed due to incidence of atypical and anaplastic meningomas in male patients. Although most of the studies show ed similar observation in terms of PR positivity in female patients while in male patients it largely differs and found 55-58% PR positivity. The current study found PR expression was more frequently in meningothelial and transitional subtypes than in the fibroblastic histological type which resemble the earlier studies.

In Grade I meningiomas, the positive immunostaining rate for PR was significantly higher than in high-grade tumors which is like prior studies. The present study revealed 79.71% PR positivity in Grade I meningiomas however Gursan et al and Mukherjee et al showed 76% and 70% positivity in the same grade respectively. We found that 100% recurrent meningiomas were PR-negative and similar to Fewings et al while it was 80% in study by Mukherjee et al there is a significant association between PR negativity and tumor recurrence.

There was a "strong" converse relationship between Ki-67 LI and PR expression. This was evident from the Ki-67 LIs were significantly higher in the PR-negative meningiomas than in the PR-positive tumors and this outcome is supported by some other studies. This was more evident in case of Grade I meningiomas and also in non-recurrent tumors, however six out of six high-grade meningiomas reveal ed PR negativity and high mean Ki-67 LI (6.50%). This effect is relatively analogous to Gursan et al and Nagashima et al found negative PR staining and high Ki-67 LI (6.50% to 7.37%) in high-grade meningiomas.

Hence, in addition to H and E staining, combining Ki-67 LI and PR expression can help not only in distinguishing between grades of meningiomas but also can help to pick which cases within the group of Grade I meningiomas are likely to recur.
5. Conclusion
The Results revealed that immnodetection of PR and ki-67 L1 expressions in meningiomas are the important indicators for assessing prognosis and recurrence rate in meningiomas.

6. Conflict of Interest
None

7. Source of Funding
None

References

1. Alahmadi H, Croul SE. Pathology and genetics of meningiomas. Semin Diagn Pathol. 2011;28:314–324.
2. Herrmann AJ, Ooi S, Launay JL, Scary BF, Deighton J, et al. Proteomic data in meningiomas: Post-proteomic analysis can reveal novel pathophysiological pathways. J Neurooncol. 2011;104:401–410.
3. Konstantinidou AE, Pavlopoulos PM, Patsouris E, Kaklamanis L, Davaris P. Expression of apoptotic and proliferation markers in meningiomas. J Pathol. 1998;186:325–330.
4. Mosnier FJ, Perret AG, Brunon J, Boucheron S. Expression of bcl-2 oncoprotein in meningiomas. Am J Clin Path. 1996;106:652–659.
5. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002;94:1626–1635.
6. Hsu DW, Efird JT, Whyle ETH. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg. 1997;86:113–120.
7. Frempong MT, Ghartey FN, Asante-Poku S, Wiafe-Addai. A cross sectional view of estrogen receptors in 32 human breast cancer tissues in Ghana. J Med Sci. 2008;8:420–424.
8. Amin A. Protective effect of green alage against 7,12-dimethylbenzanthracene (DMBA)-induced breast cancer in rats. Int J Cancer Res. 2009;5:12–24.
9. Sahib HB, Ismail Z, Othman NH, Abdul-Majid A. Orthosiphon stamineus benth. methanolic extract enhances the anti-proliferative effects of tamoxifen on human hormone dependent breast cancer. Int J Pharmacol. 2009;5:273–276.
10. El-Kott, Owayss AA. Protective effects of propolis against the amitraz hepatotoxicity in mice. J Pharmacol Toxicol. 2008;3:402–408.
11. Rezaei JH, Ashegh M, Behzadi HM, Khodadadi F, Heidari M. The investigation of p53 and Ki-67 gene mutations in relation with helicobacter pylori infection in patients with gastric cancer. J Med Sci. 2008;8:564–568.
12. Bin-Meferij MM. Histological and immunohistochemical studies for evaluation of the role of microalgae Status of Ki-67, Estrogen and Progesterone Receptors in Various Subtypes of Intracranial Meningiomas - SciAlert Responsive Version Spirulina sp. against cancer in experimental animals. Int J Cancer Res. 2009;12:36–43.
13. Sohrabi MPA, Kalati S, Vatansever MM, Abbasi, Roshangar L. Effect of dietary and topical celecoxib on expression of bcl-2, bax, c-erb-B2 and Ki67 in carcinogen-induced tongue carcinoma in rat. Pak J Biol Sci. 2009;12:750–757.
14. Talghini SM, Halimi, Baybordi H. Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pak J Biol Sci. 2009;12:929–333.
15. Priya DK, Gayathiri R, Gunasekaran GR, Murugan S, Sakhisekearan D. Inhibitory effect of sulfuraphane against benzo(a)pyrene induced lung cancer by modulation of biochemical signatures in female swiss albino mice. Asian J Biochem. 2011;6:395–405.
16. El-Shaer MA, El-Sharkawy SL, Hassan NS. Prognostic significance of steroid hormone receptors and DNA content in meningiomas. J Med Sci. 2007;7:347–353.
17. Gursan N, Gundogdu C, Albayrak A, Kabalar ME. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Int J Neurosci. 2002;112:463–70.
18. Mukherjee S, Ghosh SN, Chatterjee U, Chatterjee S. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningioma. Neurology India. 2011;59:817–822.
19. Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery, 1995;37:478–482.
20. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol. 1996;91:504–510.
21. Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors. Hum Pathol. 1998;29:1420–1427.
22. Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, Trotzenburg MV, et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurgical Review. 2004;27:238–245.
23. Miyagami M, Shibuya T, Miyagi A, Tsabokawa T. Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies. No To Shinkei. 1996;48:39–43.
24. Halpern DF, Tan U. Stereotypes and steroids: Using a psycho biosocial model to understand sex differences. Brain Cognit. 2001;45:392–414.
25. Pericot-Applanat M, Groyer-Picard MT, Kujas M. Immunocytotoxic study of progesterone receptor in human meningioma. Acta Neurochirurgica. 1992;115:20–30.
26. Black P. Meningiomas. Neurosurgery. 1993;32:643–657.
27. Fewings PE, Battersby RD, Timperley WR. Long-term follow up of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence. J Neurosurg. 2000;92:401–405.

Author biography
Sagar N Shahane Assistant Professor

Cite this article: N Shahane S. Estrogen and progesterone receptor status in meningioma and its correlation with mib-1 labeling index. Indian J Neurosci 2019;5(4):232–235.